In this issue:
PD-1 or PD-L1 inhibitors vs conventional drugs in advanced cancer
Pembrolizumab vs paclitaxel for mG/GOC
FOLFIRI with regorafenib as second-line therapy for mCRC
Can a mailed FIT outreach increase rates of CRC screening?
FIT-based outreach programmes for Medicaid beneficiaries
FIT kits: cost-effective for reducing CRC-related death
XELIRI vs irinotecan alone in refractory advanced biliary tract cancer
Psychological intervention for patients with advanced cancer
MBCT and Internet-based MBCT for patients with cancer
Comparing CTX regimens in borderline/ locally advanced pancreatic cancer
Please login below to download this issue (PDF)